title: Postnatal resveratrol supplementation improves cardiovascular function in male and female intrauterine growth restricted offspring.
abstract: Intrauterine growth restriction (IUGR) may predispose offspring to an increased susceptibility of developing cardiovascular disease (CVD) in adult life. The window of opportunity to treat later life CVD programmed in fetal life is critical. The aim of this study was to identify the effect of resveratrol treatment of IUGR offspring at a time of known CV dysfunction. Sprague-Dawley male and female rat offspring who experienced normoxia (21% O2; control) or hypoxia (11% O2; IUGR) in utero were fed a high-fat (HF) diet (3-21 weeks of age) or a HF diet (3-21 weeks of age) supplemented with resveratrol from 13 to 21 weeks of age. At 21 weeks of age, echocardiographic data showed that male IUGR offspring had mild in vivo diastolic dysfunction, whereas female IUGR offspring had early signs of cardiac diastolic dysfunction that was not altered by resveratrol treatment. Notably, male and female IUGR offspring demonstrated equal susceptibility to ex vivo cardiac dysfunction recovery after ischemia/reperfusion (I/R) injury and this was improved by resveratrol treatment, independent of sex. Resveratrol increased cardiac phospho-adenosine monophosphate kinase (p-AMPK) levels in only female IUGR offspring. IUGR or resveratrol did not alter cardiac superoxide levels. However, in male offspring, an overall effect of IUGR in reducing cardiac catalase levels was observed that was not altered by resveratrol. Interestingly, in only female IUGR offspring, resveratrol significantly increased cardiac superoxide dismutase (SOD) 2 levels. In conclusion, resveratrol treatment of adult IUGR offspring, at the time of known CV dysfunction, improved cardiac function recovery in both sexes and the mechanisms involved were partially sex-specific.
authors.affiliation: Department of Obstetrics and Gynecology, University of Alberta, Edmonton, Alberta, Canada.|Women and Children's Health Research Institute, University of Alberta, Edmonton, Alberta, Canada.
authors.forename: Amin
authors.initials: A
authors.lastname: Shah
authors.affiliation: Department of Obstetrics and Gynecology, University of Alberta, Edmonton, Alberta, Canada.|Women and Children's Health Research Institute, University of Alberta, Edmonton, Alberta, Canada.
authors.forename: Anita
authors.initials: A
authors.lastname: Quon
authors.affiliation: Department of Obstetrics and Gynecology, University of Alberta, Edmonton, Alberta, Canada.|Women and Children's Health Research Institute, University of Alberta, Edmonton, Alberta, Canada.
authors.forename: Jude S
authors.initials: JS
authors.lastname: Morton
authors.affiliation: Department of Obstetrics and Gynecology, University of Alberta, Edmonton, Alberta, Canada sandra.davidge@ualberta.ca.|Women and Children's Health Research Institute, University of Alberta, Edmonton, Alberta, Canada.|Department of Physiology, University of Alberta, Edmonton, Alberta, Canada.
authors.forename: Sandra T
authors.initials: ST
authors.lastname: Davidge
mesh_terms: D055372:AMP-Activated Protein Kinases / Q000378:metabolism; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology* / Q000517:prevention & control; D004435:Eating / Q000187:drug effects; D005260:Female; D005317:Fetal Growth Retardation / Q000378:metabolism / Q000503:physiopathology; D006321:Heart / Q000187:drug effects* / Q000503:physiopathology; D008297:Male; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D018384:Oxidative Stress / Q000187:drug effects; D010766:Phosphorylation; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077185:Resveratrol; D013267:Stilbenes / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D013267:Stilbenes; C543928:Prkaa2 protein, rat; D055372:AMP-Activated Protein Kinases; D000077185:Resveratrol
keywords: 
  IUGR
  ; Cardiac function; resveratrol